Women's Experiences of Day-and-Night Closed-Loop Insulin Delivery During Type 1 Diabetes Pregnancy.
J Diabetes Sci Technol
MetadataShow full item record
Farrington, C., Stewart, Z., Hovorka, R., & Murphy, H. (2018). Women's Experiences of Day-and-Night Closed-Loop Insulin Delivery During Type 1 Diabetes Pregnancy.. J Diabetes Sci Technol, 12 (6), 1125-1131. https://doi.org/10.1177/1932296818800065
AIMS: Closed-loop insulin delivery has the potential to improve day-to-day glucose control in type 1 diabetes pregnancy. However, the psychosocial impact of day-and-night usage of automated closed-loop systems during pregnancy is unknown. Our aim was to explore women's experiences and relationships between technology experience and levels of trust in closed-loop therapy. METHODS: We recruited 16 pregnant women with type 1 diabetes to a randomized crossover trial of sensor-augmented pump therapy compared to automated closed-loop therapy. We conducted semistructured qualitative interviews at baseline and follow-up. Findings from follow-up interviews are reported here. RESULTS: Women described benefits and burdens of closed-loop systems during pregnancy. Feelings of improved glucose control, excitement and peace of mind were counterbalanced by concerns about technical glitches, CGM inaccuracy, and the burden of maintenance requirements. Women expressed varied but mostly high levels of trust in closed-loop therapy. CONCLUSIONS: Women displayed complex psychosocial responses to day-and-night closed-loop therapy in pregnancy. Clinicians should consider closed-loop therapy not just in terms of its potential impact on biomedical outcomes but also in terms of its impact on users' lives.
closed-loop, day-and-night, pregnancy, type 1 diabetes, Adult, Blood Glucose, Blood Glucose Self-Monitoring, Circadian Rhythm, Cost of Illness, Cross-Over Studies, Diabetes Mellitus, Type 1, Female, Humans, Insulin, Insulin Infusion Systems, Interviews as Topic, Patient Satisfaction, Pregnancy, Pregnancy in Diabetics, Risk Assessment, Trust
This project is supported by grants from Diabetes UK (BDA 07/0003551), National Institute for Health Research (NIHR CDF 2013-06-035), Gates Cambridge Trust, and Jean Hailes for Women’s Health. CF is funded by JDRF. RH receives additional support for the artificial pancreas work from JDRF, National Institute for Health Research Cambridge Biomedical Research Centre and Wellcome Strategic Award (100574/Z/12/Z).
Cambridge University Hospitals NHS Foundation Trust (CUH) (BRC 2012-2017)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Diabetes UK (None)
External DOI: https://doi.org/10.1177/1932296818800065
This record's URL: https://www.repository.cam.ac.uk/handle/1810/284976
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com